GS
SRNE

Gagnon Securities’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Gagnon Securities’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-29,568
Closed -$112K – 97
2017
Q4 		$112K Sell
29,568
-2,018
-6% -$5.26K 0.04% 87
2017
Q3 		$54K Hold
31,586
– – 0.02% 92
2017
Q2 		$63K Buy
31,586
+20,470
+184% +$39.9K 0.02% 85
2017
Q1 		$44K Hold
11,116
– – 0.02% 91
2016
Q4 		$54K Hold
11,116
– – 0.02% 91
2016
Q3 		$86K Sell
11,116
-75
-0.7% -$505 0.04% 92
2016
Q2 		$63K Buy
11,191
+60
+0.5% +$383 0.03% 88
2016
Q1 		$60K Hold
11,131
– – 0.03% 85
2015
Q4 		$97K Buy
11,131
+130
+1% +$1.1K 0.04% 80
2015
Q3 		$92K Hold
11,001
– – 0.05% 81
2015
Q2 		$194K Buy
+11,001
New +$141K 0.08% 78

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Gagnon Securities's SRNE Position: Q1 2018 in Review

Gagnon Securities sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2018, closing a stake of 29,568 shares — an estimated $112K sold.

Gagnon Securities first reported a position in SRNE in Q2 2015 and held it in 11 quarters. The position peaked at $194K in Q2 2015. 73 funds tracked by Wall St. Rank hold SRNE as of Q1 2018.

  • Gagnon Securities reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Gagnon Securities sold 29,568 Sorrento Therapeutics, Inc. shares in Q1 2018, an estimated $112K.
  • Gagnon Securities first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
  • Gagnon Securities's Sorrento Therapeutics, Inc. position peaked at $194K in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2018.

Based on Gagnon Securities's 13F filing for Q1 2018, filed 9 May 2018.